FDA Prepares To Issue Draft Biomarker Qualifications Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
The document should provide an "important boost" to employing genetic, genomic and protein-based markers to improve the efficiency of preclinical and clinical drug studies and make them more likely to succeed, Commissioner Hamburg told the Personalized Medicine Coalition.
You may also be interested in...
FDA Drug Development Tool Guidance Leaves Door Open For Advisory Committee Reviews
FDA’s proposed process for qualifying drug development tools allows for the convening of advisory committee meetings or other public discussions about complicated submissions involving proposed biomarkers or patient-reported outcome instruments.
FDA Drug Development Tool Guidance Leaves Door Open For Advisory Committee Reviews
FDA’s proposed process for qualifying drug development tools allows for the convening of advisory committee meetings or other public discussions about complicated submissions involving proposed biomarkers or patient-reported outcome instruments.
Biomarker Qualification Should Be Multi-Step Process, Regulators Say
U.S. and European regulations expect qualification of biomarkers for clinical use to be a multi-stage process that incrementally broadens a marker's application